Stock market today: S&P 500 hits fresh record close on stronger economic growth
Investing.com -- Invivyd Inc. shares rose 75% premarket Tuesday following commentary from STAT News reporter Adam Feuerstein, whose social media post highlighted the company as a potential COVID-19 vaccine alternative amid growing political skepticism toward traditional immunizations. The biotech firm, which is developing a next-generation monoclonal antibody, has seen renewed momentum after a $58 million financing round backed by RA Capital and Janus Henderson.
“$IVVD garnering attention again as potential alternative to Covid vaccines in the current anti-vaccine political climate,” Feuerstein wrote on X, referring to the broader environment where alternative therapies are gaining traction. The surge in share price marks the latest example of market sensitivity to public health policy commentary and reflects investor interest in treatments positioned outside the traditional vaccine framework.
The rally also comes amid reports of a potential policy shift in the U.S., with the Trump administration reportedly planning to roll back support for COVID-19 vaccines. According to The Daily Beast, Dr. Aseem Malhotra stated that “Health and Human Services Secretary Robert F. Kennedy Jr. and President Donald Trump are allegedly planning to phase out the COVID-19 vaccine ‘within months.’”
These developments have made Invivyd a focal point for both retail traders and institutional backers, as evidenced by the recent capital injection from long-term healthcare investors. The company had already notched a 193% stock increase in February after releasing favorable pharmacokinetic and safety data, igniting hope for non-vaccine preventative options.
With federal support for existing vaccine infrastructure facing uncertainty, market participants are watching Invivyd’s trajectory closely.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.